Introduction {#sec1}
============

Prostate cancer (PCa) is the most common malignant tumor of the urinary system in men in the western world, the second most frequent cancer and the fifth leading cause of tumor-related deaths worldwide \[[@B1],[@B2]\]. Globally, it is estimated that there will be approximately 1.3 million newly diagnosed cases of PCa and 359000 associated deaths in 2018 \[[@B1]\], making the disease a major health problem in men. The occurrence and development of PCa is influenced by both environmental and genetic factors. Risk factors associated with PCa include age, lifestyle, familial heredity, and hormonal status, but the exact etiology is unclear \[[@B3]\]. It has been shown that exposure to aromatic hydrocarbons is associated with a high risk of PCa \[[@B4]\], and racial differences and familial aggregation are amongst the genetic factors that influence the incidence and development of the disease. Therefore, an increasing number of studies are attempting to explain the occurrence, development, and prognosis of PCa through analysis of variations in the genes involved in hormone metabolism.

A single nucleotide polymorphism (SNP) is a single nucleotide variation at the genomic level, which can appear in coding or non-coding sequences. In recent years, third-generation genetic markers have attracted a lot of attention for their potential role in predicting cancer susceptibility. A number of genes including those encoding the androgen receptor (AR), prostate-specific antigen (PSA), 5a-reductase type II (SRD5A2), and cytochrome P450 (CYP) have been confirmed as PCa susceptibility genes \[[@B4]\]. The CYPs are a large superfamily of conserved proteins found in animals, plants, and microorganisms. Cytochrome P450 1A1 (CYP1A1) and 1B1 (CYP1B1) are pivotal members of the CYP1 family. Classified as a phase I enzyme, CYP1A1 is involved in aryl hydrocarbon hydroxylase activity, while CYP1B1 participates in hydroxylation of estrogens. He and Feng \[[@B5]\] reported that CYP1A1 is involved in the metabolism of estrogen and also activates procarcinogens. Furthermore, it has been shown that the CYP1A1 polymorphism is associated with PCa development \[[@B6]\]. Tokizane et al. \[[@B7]\] found that hypomethylation of the promoter/enhancer region leads to overexpression of CYP1B1 in PCa cells, and metabolites from CYP1B1 catalysis have been demonstrated to induce PCa in an animal model \[[@B8]\]. As an androgen-dependent organ, the prostate contains several enzymes, including CYP1A1 and CYP1B1, which participate in the metabolism of steroid hormones. It is evident from these reports that CYP1A1 and CYP1B1 play crucial roles in the development of PCa and are potential diagnostic and predictive markers, as well as therapeutic targets.

Previous meta-analyses investigating the relationship between CYP1A1 and CYP1B1 polymorphisms and the risk of PCa reported inconsistent results. Cui et al. \[[@B9]\] did not find the CYP1B1 rs1056836 polymorphism to be associated with PCa, while another study found the CYP1A1 rs1048943, but not rs4646903, polymorphism to be associated with a high risk of PCa \[[@B10]\]. Another study on an Indian cohort reported the CYP1A1 rs1048943 polymorphism to be associated with a lower risk of PCa, while rs4646903 was related to a high PCa risk \[[@B11]\]. Although these findings strongly suggest that CYP1A1 and CYP1B1 polymorphisms may be closely related to the susceptibility to PCa, they do not provide an across-the-board estimate of the association. In the past few years, attempts to define the exact relationship have been stymied because of differences in study designs, genotyping methods, and the ethnicity and genetics of the study populations. Therefore, the present meta-analysis, which includes previous and some recently published studies, was undertaken to gain a more precise estimation of the association of polymorphisms with PCa, and to evaluate the possible risk factors.

Materials and methods {#sec2}
=====================

Literature search strategy {#sec2-1}
--------------------------

The PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases were systematically searched independently by two authors (W.Z. and H.L.) on 15 August 2018 to retrieve eligible articles. The search terms included: 'cytochrome P450 1A1', 'cytochrome P450 1B1', 'CYP1A1', 'CYP1B1', 'prostate cancer', 'PCa', 'PC', 'gene', 'polymorphism', 'allele' and 'variation'. In addition, reference lists of the retrieved papers were manually reviewed to obtain additional studies that met the inclusion criteria.

Study selection criteria {#sec2-2}
------------------------

Studies selected for the meta-analysis had to meet the following inclusion criteria: (i) the study investigated the association between CYP1A1, CYP1B1 polymorphism, and risk of PCa, (ii) the design was a case--control study, (iii) sufficient data were reported to determine the pooled odds ratios (ORs) and 95% confidence intervals (95% CIs), and (iv) the full text was published. Meta-analyses, letters, single-case reports, duplicate studies, animal model studies, and studies without available data were excluded.

Data extraction {#sec2-3}
---------------

Two authors (W.Z. and X.W.) independently extracted the available data from included papers, and any disagreements were resolved by the third investigator (J.L.). The following information was extracted and recorded: author, year of publication, ethnicity of subjects (Asian, African, Caucasian, or mixed), the name of gene, the names of SNPs, genotyping method (PCR-restriction fragment length polymorphism \[PCR-RFLP\], Taqman, allele-specific PCR \[AS-PCR\] or Genechips), source of controls (population or hospital), total numbers of cases and controls, and the Newcastle--Ottawa Scale (NOS). Studies which investigated more than one kind of SNP were counted as individual data for the present meta-analysis. The quality of all included studies was assessed independently by the three researchers using the validated NOS, and disagreements were resolved through discussion with another researcher (H.Z.). Studies with scores of \>6 were considered as high-quality studies, and those with scores of ≤6 as low-quality studies.

Statistical analysis {#sec2-4}
--------------------

We utilized Stata 12.0 software (Stata Corp LP, College Station, TX) to conduct the meta-analysis and estimate heterogeneity between the included studies. ORs and 95% confidence intervals (CIs) were used to assess any associations between CYP1A1 and CYP1B1 polymorphisms and the risk of PCa. The pooled ORs were calculated in BB vs. AA (A: the major allele, B: the minor allele), BB + AB vs. AA, BB vs. AB + AA, B vs. A, and AB vs. AA genetic models using either the fixed-effects model or the random-effect model. In case of significant heterogeneity (*Q*-test: *I*^2^ ≥ 50% or *P*≤0.05) between studies, a random-effect model was used for analysis; otherwise, a fixed-effect model would be chosen \[[@B12]\]. Subgroup analyses were performed based on ethnicity (Caucasian, Asian, African, or mixed). Finally, sensitivity analysis was performed to examine whether the independent studies included in the meta-analysis affected the pooled results, and publication bias was evaluated by Egger's test \[[@B13]\].

Results {#sec3}
=======

Characteristics of included studies {#sec3-1}
-----------------------------------

A flow diagram of the study selection is shown in [Figure 1](#F1){ref-type="fig"}. We retrieved 207 studies from the PubMed, Embase, Cochrane Library, and CNKI databases. Initial screening excluded 63 duplicated articles, and 92 papers that did not fit the inclusion criteria were excluded after careful review of the titles and abstracts. Out of the 52 studies selected for full publication review, 21 were excluded (12 studies were not case--control studies and 9 were not related to CYP1A1/CYP1B1 or PCa). Finally, 31 articles \[[@B11],[@B14]\] including 12745 cases and 12471 controls that met the inclusion criteria were included in the final analysis. The main characteristics of these studies are summarized in [Table 1](#T1){ref-type="table"}. Genotype frequency was available in all included studies. A total of 16 Caucasian, 12 Asian, 1 African, and 2 mixed populations were represented in the 31 selected studies. Of note, three SNPs in CYP1A1 and twelve in CYP1B1 were excluded from the final analysis due to lack of sufficient research.

![The flow diagram of this meta-analysis](bsr-39-bsr20181876-g1){#F1}

###### Characteristics of the studies included in the meta-analysis

  Author                 Year   Ethnicity   Gene            SNP                                                                                   Genotyping method   Source of control   Cases/controls   NOS
  ---------------------- ------ ----------- --------------- ------------------------------------------------------------------------------------- ------------------- ------------------- ---------------- -----
  Tanaka et al.          2002   Asian       CYP1B1          rs1056827, rs2551188, rs10012, rs1056836, rs1056837                                   PCR-RFLP            Hospital            117/200          8
  Murata et al.          2001   Asian       CYP1A1          rs1048943                                                                             PCR-RFLP            Hospital            115/200          7
  Suzuki et al.          2003   Asian       CYP1A1          rs4646903, rs1048943                                                                  PCR-RFLP            Hospital            81/105           8
  Mandić et al.          2014   Caucasian   CYP1A1          rs4646903                                                                             Taqman              Hospital            120/120          7
  Fukatsu et al.         2004   Asian       CYP1B1          rs1056836                                                                             PCR-RFLP            Population          147/266          7
  Acevedo et al.         2003   Caucasian   CYP1A1          rs4646903                                                                             PCR-RFLP            Population          102/102          6
  Aktas et al.           2004   Caucasian   CYP1A1          rs4986883                                                                             AS-PCR              Hospital            100/107          7
  Beer et al.            2002   Caucasian   CYP1A1          rs1048943                                                                             PCR-RFLP            Population          117/183          7
  Beuten et al.          2008   Caucasian   CYP1B1          rs2567206, rs2551188, rs2617266, rs10012, rs1056836, rs1800440                        Taqman              Population          649/738          8
  Brureau et al.         2016   Mixed       CYP1B1          rs1056836                                                                             PCR-RFLP            Population          660/709          7
  Cáceres et al.         2005   Caucasian   CYP1A1          rs4646903                                                                             PCR-RFLP            Population          103/132          6
  Vijayalakshmi et al.   2005   Asian       CYP1A1          rs4646903, rs1048943                                                                  PCR-RFLP            Population          50/50            7
  Catsburg et al.        2012   Caucasian   CYP1B1          rs1056836                                                                             Taqman              Population          1343/800         9
  Cicek et al.           2005   Caucasian   CYP1B1          rs1056827, rs1056836                                                                  PCR-RFLP            Population          439/479          8
  Cusseno et al.         2007   Caucasian   CYP1B1          rs1056836                                                                             Taqman              Population          1101/882         6
  Lima et al.            2008   Caucasian   CYP1A1          rs4646903                                                                             PCR-RFLP            Hospital            125/100          7
  Holt et al.            2012   Caucasian   CYP1A1/CYP1B1   rs162549, rs2855658, rs1056836, rs1456432, rs4886605                                  PCR-RFLP            Population          1304/1266        8
  Gu et al.              2018   Asian       CYP1B1          rs9341266, rs162549, rs10916, rs162562, rs2551188, rs9341250, rs1056827, rs1056836    Taqman              Population          1015/1052        7
  Kachakova et al.       2016   Caucasian   CYP1B1          rs1056836, rs1056837, rs1800440, rs1056827,                                           PCR-RFLP            Hospital            246/261          6
  Kato et al.            2018   Caucasian   CYP1B1          rs2551188, rs2567206, rs2567207, rs162556, rs10175368, rs163090, rs162330, rs162331   Taqman              Population          400/405          8
  Kumar et al.           2010   Asian       CYP1A1          rs4646903, rs1048943                                                                  PCR-RFLP            Population          70/61            6
  Mittal et al.          2007   Asian       CYP1A1          rs4646903                                                                             PCR-RFLP            Population          130/140          6
  Nock et al.            2006   Mixed       CYP1A1          rs1048943                                                                             PCR-RFLP            Population          439/479          6
  Price et al.           2016   Caucasian   CYP1B1          rs1800440                                                                             Taqman              Population          1506/1380        9
  Quiñones et al.        2006   Caucasian   CYP1A1          rs4646903                                                                             PCR-RFLP            Population          60/117           6
  Rodrigues et al.       2010   Caucasian   CYP1A1/CYP1B1   rs1048943, rs1056827                                                                  AS-PCR              Population          154/154          6
  Sobti et al.           2006   Asian       CYP1B1          rs1056836                                                                             PCR-RFLP            Population          100/100          7
  Souiden et al.         2012   African     CYP1A1          rs4646903                                                                             PCR-RFLP            Population          138/138          6
  Tang et al.            2017   Asian       CYP1B1          rs10012, rs1800440                                                                    Taqman              Population          1506/1380        8
  Yang et al.            2006   Asian       CYP1A1          rs4646903, rs1048943                                                                  AS-PCR              Hospital            225/250          6
  Guan et al.            2005   Asian       CYP1A1          rs4646903, rs1048943                                                                  Genechips           Hospital            83/115           6

Meta-analysis {#sec3-2}
-------------

The results of the meta-analysis are shown in [Table 2](#T2){ref-type="table"}. Meanwhile, the forest plots for positive results are shown in [Figure 2](#F2){ref-type="fig"}.

![Forest plot for the association between gene polymorphisms and PCa\
Forest plot for rs1048943 polymorphism in overall population (B vs. A, (**A**)) and Asian population (B vs. A, (**B**); BB vs. AA, (**C**); BB vs. AA+AB, (**D**)), for rs4646903 polymorphism in Asian population (AB vs. AA, (**E**)) and Caucasian population (BB vs. AA, (**F**)). Abbreviation: vs., versus.](bsr-39-bsr20181876-g2){#F2}

###### Meta-analysis of CYP1 gene polymorphisms and PCa

  Polymorphisms   Comparisons      Number of studies   Test of association   Heterogeneity                           
  --------------- ---------------- ------------------- --------------------- --------------- --------- --- --------- ------
  CYP1A1                                                                                                             
  rs1048943                                                                                                          
    Overall       B vs. A          9                   1.20 (1.04, 1.39)     2.46            0.014     F   0.157     32.6
                  BB vs. AA        9                   1.37 (0.97, 1.93)     1.8             0.072     F   0.122     38.6
                  AB vs. AA        9                   1.24 (1.02, 1.51)     2.15            0.029     F   0.11      38.8
                  BB + AB vs. AA   9                   1.25 (1.04, 1.50)     2.37            0.018     F   0.132     35.8
                  BB vs. AA + AB   9                   1.21 (0.92, 1.61)     1.35            0.178     F   0.135     36.9
    Asian         B vs. A          6                   1.32 (1.11, 1.56)     3.23            0.001     F   0.235     26.7
                  BB vs. AA        5                   1.81 (1.20, 2.72)     2.84            0.005     F   0.649     0
                  AB vs. AA        6                   1.30 (1.03, 1.64)     2.19            0.029     F   0.151     38.3
                  BB + AB vs. AA   6                   1.38 (1.11, 1.73)     2.87            0.004     F   0.129     41.5
                  BB vs. AA + AB   6                   1.58 (1.08, 2.01)     2.38            0.019     F   0.699     0
    Caucasian     B vs. A          2                   0.86 (0.60, 1.23)     0.83            0.405     F   0.984     0
                  BB vs. AA        2                   0.66 (0.31, 1.37)     1.12            0.262     R   0.114     60
                  AB vs. AA        2                   1.16 (0.71, 1.89)     0.59            0.557     R   0.038     76.8
                  BB + AB vs. AA   2                   0.97 (0.63, 1.49)     0.15            0.883     F   0.33      0
                  BB vs. AA + AB   2                   0.63 (0.32, 1.22)     1.36            0.172     R   0.1       63.1
  rs4646903                                                                                                          
    Overall       B vs. A          12                  1.18 (1.04, 1.33)     2.62            0.009     R   0.001     65.7
                  BB vs. AA        11                  1.16 (0.88, 1.53)     1.07            0.286     F   0.111     35.9
                  AB vs. AA        12                  1.41 (1.19, 1.68)     3.99            \<0.001   R   0.007     57.5
                  BB + AB vs. AA   12                  1.36 (1.15, 1.59)     3.69            \<0.001   R   0.001     65
                  BB vs. AA + AB   12                  0.95 (0.74, 1.23)     0.36            0.72      F   0.458     0
    Asian         B vs. A          6                   1.07 (0.92, 1.26)     0.88            0.377     R   0.038     57.6
                  BB vs. AA        6                   0.88 (0.63, 1.24)     0.7             0.482     F   0.791     0
                  AB vs. AA        6                   1.43 (1.13, 1.80)     2.99            0.003     F   0.169     35.6
                  BB + AB vs. AA   6                   1.30 (1.04, 1.61)     2.31            0.021     R   0.068     51.3
                  BB vs. AA + AB   6                   0.79 (0.58, 1.07)     1.52            0.128     F   0.901     0
    Caucasian     B vs. A          5                   1.43 (1.16, 1.75)     3.41            0.001     R   0.007     71.9
                  BB vs. AA        4                   2.12 (1.29, 3.49)     2.97            0.003     F   0.2       35.4
                  AB vs. AA        5                   1.54 (1.17, 2.02)     3.08            0.002     R   0.004     74
                  BB + AB vs. AA   5                   1.57 (1.21, 2.04)     3.38            0.001     R   0.001     77.5
                  BB vs. AA + AB   5                   1.49 (0.93, 2.37)     1.67            0.095     F   0.366     5.4
  CYP1B1                                                                                                             
  rs1056836                                                                                                          
    Overall       B vs. A          12                  1.02 (0.96, 1.07)     0.61            0.54      R   \<0.001   73.4
                  BB vs. AA        12                  1.04 (0.93, 1.17)     0.65            0.514     R   \<0.001   70.5
                  AB vs. AA        12                  1.03 (0.96, 1.12)     0.84            0.401     F   0.077     39.5
                  BB + AB vs. AA   12                  1.03 (0.96, 1.11)     0.77            0.441     R   0.002     63.1
                  BB vs. AA + AB   12                  1.01 (0.91, 1.12)     0.1             0.916     R   0.002     62.2
    Asian         B vs. A          4                   0.99 (0.87, 1.14)     0.09            0.932     R   \<0.001   84.6
                  BB vs. AA        4                   1.20 (0.78, 1.85)     0.85            0.398     R   0.004     77.1
                  AB vs. AA        4                   0.96 (0.81, 1.12)     0.54            0.587     R   0.026     67.7
                  BB + AB vs. AA   4                   0.97 (0.83, 1.14)     0.36            0.722     R   0.002     79.4
                  BB vs. AA + AB   4                   1.17 (0.76, 1.79)     0.71            0.477     R   0.012     72.8
    Caucasian     B vs. A          7                   1.02 (0.96, 1.09)     0.78            0.433     R   0.002     72
                  BB vs. AA        7                   1.03 (0.91, 1.16)     0.45            0.649     R   0.001     74.8
                  AB vs. AA        7                   1.07 (0.97, 1.17)     1.39            0.163     R   0.314     15.2
                  BB + AB vs. AA   7                   1.05 (0.97, 1.15)     1.19            0.234     R   0.03      57
                  BB vs. AA + AB   7                   1.00 (0.90, 1.11)     0.06            0.951     R   0.007     66.1
  rs10012                                                                                                            
    Overall       G vs. C          3                   1.05 (0.91, 1.21)     0.66            0.508     F   0.545     0
  rs162549                                                                                                           
    Overall       T vs. A          2                   1.07 (0.96, 1.19)     1.21            0.226     F   0.515     0
  rs1056827                                                                                                          
    Overall       T vs. G          5                   1.14 (1.03, 1.26)     2.47            0.014     R   \<0.001   84
  rs1056837                                                                                                          
    Overall       T vs. C          2                   0.90 (0.74, 1.11)     0.96            0.338     R   0.136     54.9
  rs1800440                                                                                                          
    Overall       G vs. A          4                   0.95 (0.85, 1.06)     0.89            0.374     F   0.477     0
  rs2551188                                                                                                          
    Overall       T vs. C          4                   0.96 (0.87, 1.07)     0.72            0.474     F   0.873     0
  rs2567206                                                                                                          
    Overall       T vs. C          2                   1.21 (1.01, 1.45)     2.03            0.042     R   0.077     68

Abbreviations: F, fixed-effect model; R, random-effect model; vs., versus.

### Analysis of the CYP1A1 rs1048943 polymorphism {#sec3-2-1}

Overall, analysis of the association between the rs1048943 polymorphism and PCa from nine independent studies revealed no significant heterogeneity by a fixed-effect model. The results, however, showed a significant association between the rs1048943 polymorphism and PCa after comparing the B allele vs. A allele, AB vs. AA and BB + AB vs. AA (OR = 1.20, 95% CI = 1.04--1.39, *P*=0.014; OR = 1.24, 95% CI = 1.02--1.51, *P*=0.029; OR = 1.25, 95% CI = 1.04--1.50, *P*=0.018; respectively). Meanwhile, no association was evident when examining BB vs. AA and BB vs. AA + AB (OR = 1.37, 95% CI = 0.97--1.93, *P*=0.072; OR = 1.21, 95% CI = 0.92--1.61, *P*=0.178; respectively).

The *Q*-test revealed no significant heterogeneity in the Asian populations when analyzed from six independent studies. Therefore, we conducted an analysis using the fixed-effect model which showed a significant association between the rs1048943 polymorphism and PCa when comparing the B allele vs. A allele, BB vs. AA, AB vs. AA, BB + AB vs. AA, and BB vs. AA + AB (OR = 1.32, 95% CI = 1.11--1.56, *P*=0.001; OR = 1.81, 95% CI = 1.20--2.72, *P*=0.005; OR = 1.30, 95% CI = 1.03--1.64, *P*=0.029; OR = 1.38, 95% CI = 1.11--1.73, *P*=0.004; OR = 1.58, 95% CI = 1.08--2.01, *P*=0.019; respectively).

In the Caucasian population, significant between-study heterogeneity was found when comparing BB vs. AA, AB vs. AA, BB vs. AA + AB by the random-effect model. There was no significant heterogeneity for B allele vs. A allele or BB + AB vs. AA models, and the results showed no association of the rs1048943 polymorphism with PCa susceptibility (B vs. A, OR = 0.86, 95% CI = 0.60--1.23, *P*=0.405; BB + AB vs. AA, OR = 0.97, 95% CI = 0.63--1.49, *P*=0.883).

### Analysis of the CYP1A1 gene rs4646903 polymorphism {#sec3-2-2}

Overall, significant between-study heterogeneity was detected for most of the genetic models, except for the BB vs. AA and BB vs. AA + AB models. Fixed-effect model analysis of these two genetic models indicated no significant association (BB vs. AA, OR = 1.16, 95% CI = 0.88--1.53, *P*=0.286; BB vs. AA + AB, OR = 0.95, 95% CI = 0.74--1.23, *P*=0.72).

In the Asian populations, there was significant between-study heterogeneity in the B allele vs. A allele and BB + AB vs. AA models, and the results showed an association between rs4646903 and PCa when comparing AB vs. AA (OR = 1.43, 95% CI = 1.13--1.80, *P*=0.003), which was not evident when comparing BB vs. AA (OR = 0.88, 95% CI = 0.63--1.24, *P*=0.482) or BB vs. AA + AB (OR = 0.79, 95% CI = 0.58--1.07, *P*=0.128).

In the Caucasian populations, significant between-study heterogeneity was found in the B allele vs. A allele, AB vs. AA, and BB + AB vs. AA models. There was a significant association between rs4646903 and PCa when comparing BB vs. AA (OR = 2.12, 95% CI = 1.29--3.49, *P*=0.003). Comparing BB vs. AA + AB, however, indicated no association (OR = 1.49, 95% CI = 0.93--2.37, *P*=0.095).

### Analysis of the CYP1B1 rs1056836 polymorphism {#sec3-2-3}

Except for AB vs. AA in the overall population, significant between-study heterogeneity was found in all other genetic models. However, the association between the CYP1B1 gene rs1056836 polymorphism and risk of PCa was not significant (AB vs. AA, OR = 1.03, 95% CI = 0.96--1.12, *P*=0.401).

### Analysis of the CYP1B1 rs10012, rs162549, rs1056827, rs1056837, rs1800440, rs2551188, and rs2567206 polymorphisms {#sec3-2-4}

The meta-analysis for associations between the rs10012, rs162549, rs1056827, rs1056837, rs1800440, rs2551188, and rs2567206 polymorphisms and PCa risk in the overall population included three, two, five, two, four, four, and four independent studies, respectively. Due to significant between-study heterogeneity indicated by the *Q*-test, rs1056827, rs1056837, and rs2567206 were analyzed using the random-effect model. The fixed model was used to analyze the rs10012, rs162549, rs1800440, and rs2551188 polymorphisms. Overall, no significant association was detected between these SNPs and PCa risk (rs10012, G vs. C, OR = 1.05, 95% CI = 0.91--1.21, *P*=0.508; rs162549, T vs. A, OR = 1.07, 95% CI = 0.96--1.19, *P*=0.226; rs1800440, G vs. A, OR = 0.95, 95% CI = 0.85--1.06, *P*=0.374; rs2551188, T vs. C, OR = 0.96, 95% CI = 0.87--1.07, *P*=0.474).

Evaluation of publication bias {#sec3-3}
------------------------------

Egger's linear regression test was used to evaluate any publication bias by funnel plot asymmetry ([Table 3](#T3){ref-type="table"}). The intercept provides an assessment of asymmetry---more deviation from zero indicates more asymmetry. Egger's linear regression test provided evidence of publication bias for the rs1048943 polymorphism in the overall population (AB vs. AA: *t* = −2.95, *P*=0.021; BB + AB vs. AA: *t* = −3.53, *P*=0.010) and in the Asian populations (BB + AB vs. AA: *t* = −3.15, *P*=0.035). Egger's publication bias plots and Funnel plots for positive results are shown in [Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}, respectively. No publication bias was found in other analyses.

![Egger's publication bias analysis\
Egger's publication bias plot for rs1048943 polymorphism in overall population (B vs. A, (**A**)) and Asian population (B vs. A, (**B**); BB vs. AA, (**C**); BB vs. AA+AB, (**D**)), for rs4646903 polymorphism in Asian population (AB vs. AA, (**E**)), and Caucasian population (BB vs. AA, (**F**)). Abbreviation: vs., versus.](bsr-39-bsr20181876-g3){#F3}

![Funnel plots for statistically significant meta-analysis\
Funnel plots for rs1048943 polymorphism in overall population (B vs. A, (**A**)) and Asian population (B vs. A, (**B**); BB vs. AA, (**C**); BB vs. AA+AB, (**D**)), for rs4646903 polymorphism in Asian population (AB vs. AA, (**E**)), and Caucasian population (BB vs. AA, (**F**)). Abbreviation: vs., versus.](bsr-39-bsr20181876-g4){#F4}

###### Egger's linear regression test to measure the funnel plot asymmetric

  Polymorphisms           Y axle intercept: a (95% CI)                                                                                                                                           
  ----------------------- ------------------------------ --------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  rs1048943 (Overall)     −2.93 (−6.19, 0.33)            0.41 (−3.32, 4.14)    −2.75 (−4.95, −0.54)[\*](#T3TFN1){ref-type="table-fn"}   −2.89 (−4.82, −0.96)[\*](#T3TFN1){ref-type="table-fn"}   0.533 (−2.45, 3.51)
  rs1048943 (Asian)       −3.39 (−7.96, 1.18)            −2.63 (−8.19, 2.92)   −2.52 (−5.26, 0.22)                                      −2.75 (−5.18, −0.33)[\*](#T3TFN1){ref-type="table-fn"}   −1.38 (−7.33, 4.56)
  rs4646903 (Asian)       2.35 (−2.77, 7.47)             0.74 (−1.30, 2.79)    1.378 (−3.65, 6.40)                                      1.69 (−4.03, 7.42)                                       0.59 (−1.04, 2.21)
  rs4646903 (Caucasian)   −7.21 (−17.40, 2.98)           −4.27 (−8.73, 0.19)   −1.64 (−31.65, 28.37)                                    −3.49 (−30.55, 23.57)                                    −3.46 (−6.38, −0.54)[\*](#T3TFN1){ref-type="table-fn"}

*P*\<0.05

Discussion {#sec4}
==========

In recent years, genetic susceptibility to cancer has been a hotspot of research in the scientific community. Emerging evidence has demonstrated the potential association between gene polymorphisms and cancer risk, particularly in the CYP1 family including CYP1A1 and CYP1B1. For instance, CYP1A1 polymorphisms are known to be associated with susceptibility to a wide variety of cancers including lung \[[@B44]\], bladder \[[@B45]\], pancreatic \[[@B46]\], and breast cancers \[[@B47]\]. Similarly, the association of CYP1B1 polymorphisms and the risk of several types of cancer has been explored \[[@B48]\]. Currently, the link between CYP1 family gene polymorphisms and PCa susceptibility is attracting widespread attention. Numerous studies have focussed on the relationship between CYP proteins and their SNPs, as well as their possible effects on the development of PCa. Both CYP1A1 and CYP1B1 are involved in the metabolism of numerous carcinogens and steroidal hormones including estrogens \[[@B51],[@B52]\]. Furthermore, Cavalieri et al. \[[@B53]\] reported that metabolites of chemical carcinogens generated by CYP1B1 catalysis can induce PCa in animal models. The CYP1A1\*2A (rs4646903) polymorphism involves a thymidine to cytosine substitution at position 3801 of the 3′-non-coding region downstream of the polyadenylation site \[[@B54]\]. Although some studies have shown that the rs4646903 variant significantly increases the activity of mutant enzymes, the results are conflicting \[[@B55]\]. The CYP1A1\*2B (rs1048943) polymorphism is the second most common CYP1A1 polymorphism, which involves an adenine to guanine transition at position 2455 of codon 462 at exon 7 \[[@B56]\]. It has been reported that the rs1048943 polymorphism induces an increase in CYP1A1 at the mRNA level \[[@B57]\], and Kisselev et al. \[[@B58]\] reported that this variant significantly increases the catalytic activity for all hydroxylation sites toward substrates including 17β-estradiol (E2) and estrone (E1), most significantly for 2-hydroxylation. The CYP1B1\*3 (rs1056836) polymorphism is located in the third exon, and can result in a leucine to valine substitution \[[@B59]\]. This variant has been associated with higher hydroxylation activity, which may consequently increase the risk of various forms of cancer including PCa \[[@B51]\]. These results suggest that polymorphisms of CYP1A1 and CYP1B1 might play a role in promoting tumorigenesis by changing the activity of hydroxylase in the process of estrogen hydroxylation to 2-hydroxyestrogen (2-OH HE) and 4-OH HEs. However, the conclusions of meta-analyses of the association between CYP1A1 and CYP1B1 polymorphisms and PCa risk have been inconsistent \[[@B6],[@B9],[@B10],[@B60]\], and so we endeavored to conduct a systematic meta-analysis to precisely estimate this association, and provide a more comprehensive and reliable conclusion.

The present study provides a systematic analysis of all available case--control studies on the CYP1A1 rs1048943 and rs4646903; and CYP1B1 rs1056836, rs10012, rs162549, rs1056827, rs1056837, rs1800440, rs2551188, and rs2567206 polymorphisms and the risk of PCa. Previously, no significant associations have been found between the CYP1B1 rs10012, rs162549, rs1800440, and rs2551188 polymorphisms and PCa risk in the overall population. A possible explanation is that PCa is a multigenic disease, and the effect of a single polymorphism may therefore be limited. On the other hand, our study demonstrated that the rs1048943 polymorphism was associated with PCa susceptibility in the overall population. Results were similar in the Asian populations; however, no effect was detectable in men of Caucasian descent. Furthermore, our meta-analysis provided evidence that the rs4646903 polymorphism in the AB genotype compared with AA, and BB genotype compared with AA were considered as risk factors for PCa in Asian and Caucasian populations, respectively. However, the CYP1A1 rs4646903 polymorphism was not associated with an increased risk of PCa overall. The effect of polymorphisms on PCa susceptibility is influenced by ethnicity. Data from the National Central for Biotechnology Information (NCBI) show that the B allele (the minor allele) of rs4646903 is present in 34.0% of the Asian population, 10.7% of the Caucasian population, and 23.4% of the African-American population. However, African Americans are reported to have the highest incidence of PCa, which not only emphasizes the racial background of the disease \[[@B61]\], but also confirms the interaction between genetic and environmental factors in PCa. The interaction of genetic and lifestyle factors including dietary fat, obesity, and sexual factors could explain these ethnic differences to some extent. Undoubtedly, a larger study would provide more insight into the association of the rs1048943 and rs4646903 polymorphisms with PCa susceptibility in different ethnicities, especially African Americans.

A meta-analysis performed by Zhang et al. \[[@B60]\] showed that the CYP1B1 rs1056836, rs1800440, and rs1056827 polymorphisms were associated with susceptibility to PCa, which contradicts the results of Cui et al. \[[@B9]\] who found no association between the CYP1B1 rs1056836 polymorphism and PCa risk in the overall and Caucasian populations. No significant association with PCa susceptibility was detected for rs1800440 in our study; however, we understand that with much larger populations and more updated studies, our results may be more reliable. In agreement with our results, Ding et al. \[[@B6]\] found that the CYP1A1 rs4646903 polymorphism was responsible for increasing the risk of developing PCa. Li et al. \[[@B10]\], on the other hand, reported that the rs1048943---and not rs4646903---polymorphism was associated with PCa susceptibility, in line with the results of the present analysis.

Between-study heterogeneity is one of the pivotal issues affecting the results of the present meta-analysis. Subgroup analysis based on ethnic groups revealed a decrease in the heterogeneity amongst studies. These results indicate that ethnic subgroups contribute significantly to the high heterogeneity observed in our analysis. Due to the limited studies of hospital-based controls and genotyping methods other than PCR-RFLP, we were unable to conduct subgroup analysis based on the source of the controls and genotyping methods. However, their impact on heterogeneity should not be ignored. It is well known that using different detection methods to determine genotypes increases the heterogeneity between studies. Therefore, additional studies with different sources of control groups and genetic methods are still necessary in order to assess the impact of these polymorphisms on PCa risk. Studies that include hospital-based control groups and genotyping methods other than PCR-RFLP such as AS-PCR, Taqman, and Genechips are particularly important. Publication bias was observed in some comparisons of the present meta-analysis, which may be because the present study only included English and Chinese publications, possibly resulting in selective bias.

There are several potential limitations of this meta-analysis that should be considered. First, patients with benign prostatic hyperplasia (BPH) were enrolled as controls in our study, which may have an effect on the final results. Second, accurate determination of the association between the CYP1B1 rs1056836 polymorphism and the risk of PCa was not possible due to significant heterogeneity in the overall, Caucasian, and Asian populations. Third, our results were based on unadjusted estimates. A more reliable estimate could have been achieved if individual data such as age and other environmental factors were available.

Conclusion {#sec5}
==========

To summarize, this meta-analysis suggests that the CYP1A1 rs1048943 and rs4646903 polymorphisms are associated with PCa risk, especially in the Asian and Caucasian populations, respectively. No significant associations were detected for the CYP1B1 rs10012, rs162549, rs1800440, or rs2551188 polymorphisms. Larger studies are necessary to verify our findings and elucidate the exact association between CYP1A1 and CYP1B1 polymorphisms and susceptibility to PCa.
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